Biogen Idec e Abbott presentano i risultati positivi relativi all'esperimento …ANSA.itOggi Biogen Idec (NASDAQ: BIIB) e Abbott (NYSE: ABT) hanno presentato ulteriori risultati dalla fase 2b dello studio SELECT, il primo di due studi per la regist…
Abbott Touts $4 Billion in Drug Sales as It Pitches SpinoffBusinessWeekDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business wi…
Abbott Touts $4 Billion in New Drug Sales as It Pitches SpinoffBloombergDaclizumab, the multiple sclerosis treatment, should be on sale by 2015, as will compounds being tested for hepatitis C, the company said. At the same time, the new drug business w…
Ocrelizumab Benefits in MS Maintained to 96 WeeksMedscapeRituximab, an anti-CD20 monoclonal antibody that selectively reduces CD20-positive B-cells, showed "proof of concept" efficacy in MS in phase 1 and 2 investigations, they say. Ocrelizum…
USA TodayAbbott Executive Sees Some Pipeline Drugs With Yearly Sales Over $1BWall Street JournalHowever, several of these drugs, including daclizumab, may not make it to market until around 2015, assuming successful clinical trials and regulatory appro…
JPMorgan Chase & Co. (JPM) Analysts Reiterate a "Neutral" Rating on Biogen …LocalizedUSAIt includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interfero…
MedIndiaRituximab may Help Treat Chronic Fatigue SyndromeMedIndiaThe anti-cancer drug Rituximab may help alleviate symptoms of chronic fatigue syndrome (CFS), suggesting that the source of the disease could lie in the immune system. …Rituximab trial …
MedIndiaRituximab proven to treat ME/CFSPharmaceutical Business ReviewResearchers from Haukeland University Hospital in Bergen, Norway, have announced the efficacy of drug candidate, Rituximab in treating patients with lymphoma and myalgic encephalomye…
MedIndiaCancer Drug May Also Treat Chronic Fatigue SyndromeWebMDThe drug, rituximab (Rituxan), works by depleting immune cells called B-cells. It is FDA approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, a…
Abbott May Be Doing The Right Thing At The Wrong TimeSeeking AlphaBeyond that is a joint venture with Biogen Idec (BIIB) for daclizumab in the increasingly-crowded next-gen multiple sclerosis space and a slate of Hep C drugs that don't seem so obvi…